Skip to main content
OpenTrials
Completed

NCT Number: NCT00034944

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Major Depressive Disorder Depressive Disorder Depressive Disorder, Major Mental Disorders Mood Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

The duration of treatment is 8 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Major depressive disorder

Treatment and study plan

MK0869, aprepitant

Drug

Comparator: placebo

Drug

Primary outcomes

  1. HAMD-17 total score at week 8. Tolerability.

Secondary outcomes

  1. CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Important dates

Study start
2002
Primary completion
2003
Study completion
2003
First posted
May 3, 2002
Registry last updated
May 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.